Currently, there are 146.38M common shares owned by the public and among those 124.41M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 0.4922, down -10.06%. The company’s stock has a 5-day price change of -6.23% and -55.93% over the past three months. VERU shares are trading -38.79% year to date (YTD), with the 12-month market performance down to -92.35% lower. It has a 12-month low price of $0.36 and touched a high of $5.85 over the same period. VERU has an average intraday trading volume of 1.55 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.05%, -36.00%, and -55.10% respectively.
Institutional ownership of Veru Inc (NASDAQ: VERU) shares accounts for 18.24% of the company’s 146.38M shares outstanding.
It has a market capitalization of $64.51M and a beta (3y monthly) value of -0.28. The earnings-per-share (ttm) stands at -$1.13. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.06% over the week and 11.77% over the month.
Analysts forecast that Veru Inc (VERU) will achieve an EPS of $Verve Therapeutics, Inc. for the current quarter, $11.46 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Vera Therapeutics, Inc. while analysts give the company a high EPS estimate of $VERS. Comparatively, EPS for the current quarter was $Verb Technology Company, Inc. a year ago.
Looking at the support for the VERU, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on June 07, 2023, with the firm’s price target at $1.
